Related Experiment Video
Updated: May 27, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Management of type IIb dyslipidemia
Hidenori Arai1, Shun Ishibashi, Hideaki Bujo
1Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. harai@kuhp.kyoto-u.ac.jp
Journal of Atherosclerosis and Thrombosis
|December 6, 2011
Summary
This study addresses the lack of specific guidelines for managing type IIb dyslipidemia, a common condition linked to high cardiovascular disease risk. It proposes a new guideline to improve patient outcomes and prevent atherosclerosis cardiovascular diseases.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Lipidology
Background:
- Dyslipidemia management guidelines exist for LDL, triglycerides, and HDL cholesterol.
- Type IIb dyslipidemia, common alongside types IIa and IV, lacks specific treatment guidelines.
- Type IIb dyslipidemia is associated with atherogenic lipid profiles and comorbidities like diabetes, metabolic syndrome, and CKD.
Purpose of the Study:
- To develop a specific guideline for the management of type IIb dyslipidemia.
- To address the high cardiovascular disease risk associated with type IIb dyslipidemia.
- To provide a framework for preventing atherosclerosis cardiovascular diseases in patients with this lipid profile.
Main Methods:
- Review of existing atherosclerosis cardiovascular disease prevention guidelines.
- Analysis of the clinical significance and associated risks of type IIb dyslipidemia.
- Development of evidence-based recommendations for type IIb dyslipidemia management.
Main Results:
- Identified type IIb dyslipidemia as a significant risk factor for cardiovascular disease.
- Highlighted the association of type IIb dyslipidemia with atherogenic lipid profiles and metabolic disorders.
- Established the need for tailored management strategies for type IIb dyslipidemia.
Conclusions:
- A dedicated guideline for type IIb dyslipidemia management is crucial for cardiovascular disease prevention.
- Effective management of type IIb dyslipidemia can mitigate risks associated with comorbid conditions.
- The proposed guideline aims to improve the care of patients with this prevalent form of dyslipidemia.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...